Literature DB >> 18226000

Treatment of nephrogenic systemic fibrosis: limited options but hope for the future.

Douglas R Linfert1, Jane O Schell, Derek M Fine.   

Abstract

Nephrogenic systemic fibrosis has now been linked to gadolinium-based contrast exposure in those with compromised kidney function. When present, symptoms can be quite devastating for the patient including severe pain and immobility. Unfortunately there is a lack of a universally effective therapy at this time and the literature, reviewed in this article, is comprised of primarily case reports and small case series allowing few conclusions to be drawn. It is widely recognized that supportive management with physical therapy and aggressive pain management is essential. Resolution of renal function in acute kidney injury appears to attenuate disease in most cases and transplantation has been associated with variable success. Therapies with anecdotal benefit include extracorporeal photopheresis and intravenous sodium thiosulfate. Other interventions have shown limited success. As the mechanism becomes more readily understood, it is hoped that targeted therapy might prove more effective than currently available remedies. In all likelihood prevention will prove to be most effective in avoiding this devastating complication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226000     DOI: 10.1111/j.1525-139X.2007.00407.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  7 in total

Review 1.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

Review 2.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 3.  Gadolinium and nephrogenic systemic fibrosis: an update.

Authors:  Alex Weller; Joy L Barber; Oystein E Olsen
Journal:  Pediatr Nephrol       Date:  2013-10-22       Impact factor: 3.714

4.  Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis.

Authors:  Nelson Leung; Mark R Pittelkow; Christine U Lee; Jonathan A Good; Matthew M Hanley; Thomas P Moyer
Journal:  NDT Plus       Date:  2009-04-23

5.  Nephrogenic systemic fibrosis (NSF): the role of tamoxifen.

Authors:  Rachel Davison; Paul Mead
Journal:  NDT Plus       Date:  2010-07-12

6.  A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.

Authors:  Sadichhya Lohani; Jon Golenbiewski; Abhishek Swami; Alexandra Halalau
Journal:  BMJ Case Rep       Date:  2017-10-11

Review 7.  Nephrogenic systemic fibrosis: mini-review.

Authors:  Juliano Sacramento Mundim; Sabrina de Castro Lorena; Rosilene Motta Elias; João Egídio Romão Júnior
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.